Monitor whether the company can secure additional financing given the going concern warning and depleted cash position. Watch for further dilution from the convertible notes and warrants, and any updates on clinical trial progress that could generate revenue.
Drugs in focus
ABVC drug pipeline →ABV-1504
● Neutral Named in this 424B4- Impact
- Not rated
- Phase
- Not stated
- Time to market
- Not stated
- Next catalyst
- None dated
Executive Summary
ABVC BioPharma filed four 424B4 prospectus supplements on November 13, 2026, covering 11,714,683 shares of common stock plus 4,400,187 shares underlying warrants (3,400,187 and 1,000,000), all incorporating the company's Q3 2026 Form 10-Q. The 10-Q shows zero revenue, a $3.89 million net loss for the nine months ended September 30, 2026, a $5.79 million working capital deficit, and substantial doubt about the company's ability to continue as a going concern. The company raised $3.39 million gross via an October 30, 2026 convertible note private placement (net $2.22 million) and settled $625,000 with Lind, but the ongoing dilution and liquidity crisis dominate the picture.
Key Facts
- Four 424B4 supplements filed Nov 13, 2026: 11,714,683 common shares plus 4,400,187 shares underlying warrants (3,400,187 + 1,000,000)
- Q3 2026 (nine months ended Sept 30, 2026): revenue $0, net loss $3,890,550, working capital deficit $5,788,170
- Cash and cash equivalents fell to $11,294 as of Sept 30, 2026 from $681,480 at Dec 31, 2025
- Substantial doubt about ability to continue as a going concern
- Oct 30, 2026: raised $3,387,500 gross ($4,106,060 principal) via OID senior convertible notes, net $2,216,927 to company
- Oct 26, 2026: Lind settlement agreement, $625,000 payment, Lind warrant increased 20% to 477,600 warrants
- As of Nov 9, 2026: 26,976,625 shares outstanding
- 19 offering/registration filings in last 24 months, including this one
Financial Impact
Zero revenue; net loss of $3,890,550 for nine months ended Sept 30, 2026; working capital deficit of $5,788,170; cash of $11,294; $3,387,500 gross raised via convertible notes on Oct 30, 2026
Risk Factors
- Going concern risk: substantial doubt about ability to continue operations
- Severe liquidity constraints with only $11,294 cash as of Sept 30, 2026
- High dilution risk from 19 offering/registration filings in 24 months and outstanding convertible notes and warrants
- Zero revenue with no near-term path to profitability
- Material weakness in internal controls over financial reporting
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B4 Filing (ABVC), Batch item 1 | 0001213900-26-119790 |
| Document: 0001213900-26-119790-index-headers.html | 0001213900-26-119791 |
| Document: 0001213900-26-119790-index.html | 0001213900-26-119789 |
| Document: 0001213900-26-119790.txt | 0001213900-26-119788 |
| 424B4 Filing (ABVC), Batch item 5 | 0001213900-26-119791 |
| 424B4 Filing (ABVC), Batch item 6 | 0001213900-26-119789 |
Track record
8 reports on ABVC
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +41.67% at T+60 after the Jul 2, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago 424B4 Bearish 6/10 Viewing Entry $0.9700 Now $0.9400 +3.09% settles Dec 15
- Nov 10, 20266d ago S-3/A Bearish 5/10 Entry $0.9921 Now $0.9400 +5.25% settles Dec 10
- Nov 2, 202614d ago Press Release Bearish 6/10 Entry $0.9801 Now $0.9400 +4.09% settles Dec 1
- Nov 2, 202614d ago 8-K Bearish 6/10 Entry $0.9801 Now $0.9400 +4.09% settles Dec 1
- Sep 29, 20266w ago DEF 14A Bearish 6/10 Entry $1.04 to $1.05 Now $0.9400 +9.62% ▼ −0.96% −0.25% vs SPY
- Aug 3, 202615w ago 8-K Neutral 3/10 Entry $1.07 to $0.8254 Now $0.9400 −12.15% ▼ −22.86% −21.62% vs SPY
- Jul 2, 202619w ago 8-K Bearish 6/10 Entry $1.80 to $1.08 Now $0.9400 +47.78% ▲ +40.00% +39.59% vs SPY
- Mar 3, 202636w ago 8-K Bearish 8/10 Entry $1.45 to $1.08 Now $0.9400 +35.17% ▲ +25.52% +21.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers